Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and weight-loss management, but they have also led to some unfortunate outcomes. A recent study in JAMA Psychiatry has raised concerns that GLP-1 medications may be misused by people with eating disorders.

The Trump administration will launch its pilot program on Wednesday. It lasts 18 months, and estimated costs to taxpayers have not been disclosed.